Adocia
Adocia has built a unique expertise in diabetes and obesity. Over the years, Adocia has consolidated a rich specialty product portfolio which is one of the broadest and most differentiated for the treatment of metabolic diseases.
- Home
- >
- Adocia
About
Adocia is a French
clinical-stage biotech company
The core activities of the company are to innovate, to discover and to develop new therapeutic solutions to improve the lives of people suffering from chronic metabolic diseases, such as diabetes and obesity. Adocia innovative products share a common goal: to improve treatments, bringing new medical benefits to patients and covering unmet medical needs. Relying on disruptive technology platforms, Adocia solutions range from innovative formulations of already-approved peptides and proteins to cell therapy.
Since its creation, Adocia has built a unique expertise in diabetes and obesity, the two diseases being closely interlinked. Innovative formulations of insulins, ad other metabolic hormones – hormones playing a pivotal role in diabetes and obesity – are the focus of Adocia. Over the years, Adocia has consolidated a rich specialty product portfolio which is one of the broadest and most differentiated for the treatment of type 1, type 2 diabetes and obesity.
History
A Story of Family Entrepreneurs
Adocia was founded in 2005 by Gérard Soula and his two sons Olivier and Rémi.
These three high-level scientists each had a PhD in polymer science and extensive experience in protein delivery. They also had one idea in mind: to take up the challenge of an innovative medicine for everyone in the world. They surrounded themselves with a team of highly qualified researchers and deigned the BioChaperone® technology.
Since its founding, Adocia has created innovations in several therapeutic domains based on its BioChaperone® technology, such as the healing of chronic wounds and the treatment of diabetes with insulin therapy.
